
FDA Reviews 7 Popular Peptides — BPC-157, TB-500, Semax & More — for the 503A Compounding List
The FDA's Pharmacy Compounding Advisory Committee is reviewing BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon and DSIP for the 503A bulks list on July 23–24, 2026 — with the agency proposing none be added. Here's what's at stake.
Read article






